Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gary Gilliland

Showing results (131-140 of 182) with videos related to

Pageof 19
Sort By:
Journal of Molecular Biology|March 16, 2010
Human framework adaptation of a mouse anti-human IL-13 antibodyJohan Fransson, Alexey Teplyakov, Gopalan Raghunathan, et al.
Cell|January 27, 2007
FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stressZuzana Tothova, Ramya Kollipara, Brian J Huntly, et al.
Blood|January 25, 2008
The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenesGerlinde Wernig, Jeffrey R Gonneville, Brian J Crowley, et al.
Cell Stem Cell|September 11, 2012
mTOR complex 1 plays critical roles in hematopoiesis and Pten-loss-evoked leukemogenesisDemetrios Kalaitzidis, Stephen M Sykes, Zhu Wang, et al.
Blood|January 14, 2009
Constitutive JAK3 activation induces lymphoproliferative syndromes in murine bone marrow transplantation modelsMelanie G Cornejo, Michael G Kharas, Miriam B Werneck, et al.
Cell|January 27, 2007
FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasisJi-Hye Paik, Ramya Kollipara, Gerald Chu, et al.
Nature Genetics|March 17, 2009
A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasmsOuti Kilpivaara, Semanti Mukherjee, Alison M Schram, et al.
Oncogene|August 11, 2005
FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignanciesJing Chen, Benjamin H Lee, Ifor R Williams, et al.
Cancer Research|November 15, 2012
STAT5 is crucial to maintain leukemic stem cells in acute myelogenous leukemias induced by MOZ-TIF2Winnie F Tam, Patricia S Hähnel, Andrea Schüler, et al.
The New England Journal of Medicine|February 3, 2007
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosisLinda M Scott, Wei Tong, Ross L Levine, et al.
Pageof 19

Showing results (131-140 of 182) with videos related to

Sort By:
Pageof 19
Journal of Molecular Biology|March 16, 2010
Human framework adaptation of a mouse anti-human IL-13 antibodyJohan Fransson, Alexey Teplyakov, Gopalan Raghunathan, et al.
Cell|January 27, 2007
FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stressZuzana Tothova, Ramya Kollipara, Brian J Huntly, et al.
Blood|January 25, 2008
The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenesGerlinde Wernig, Jeffrey R Gonneville, Brian J Crowley, et al.
Cell Stem Cell|September 11, 2012
mTOR complex 1 plays critical roles in hematopoiesis and Pten-loss-evoked leukemogenesisDemetrios Kalaitzidis, Stephen M Sykes, Zhu Wang, et al.
Blood|January 14, 2009
Constitutive JAK3 activation induces lymphoproliferative syndromes in murine bone marrow transplantation modelsMelanie G Cornejo, Michael G Kharas, Miriam B Werneck, et al.
Cell|January 27, 2007
FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasisJi-Hye Paik, Ramya Kollipara, Gerald Chu, et al.
Nature Genetics|March 17, 2009
A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasmsOuti Kilpivaara, Semanti Mukherjee, Alison M Schram, et al.
Oncogene|August 11, 2005
FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignanciesJing Chen, Benjamin H Lee, Ifor R Williams, et al.
Cancer Research|November 15, 2012
STAT5 is crucial to maintain leukemic stem cells in acute myelogenous leukemias induced by MOZ-TIF2Winnie F Tam, Patricia S Hähnel, Andrea Schüler, et al.
The New England Journal of Medicine|February 3, 2007
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosisLinda M Scott, Wei Tong, Ross L Levine, et al.
Pageof 19